About this Organization
WEED, Inc., (OTC Pink: BUDZ), is a public company focused on purchasing land and building Commercial Grade “Cultivation Centers” to consult, assist, manage & lease to Licensed Dispensary owners and organic grow operators on a contract basis, with a concentration on the legal and medical marijuana sector.
The Company’s plan is to become a True “Seed-to-Sale” company providing infrastructure, financial solutions and real estate options in this new emerging market.
Similar Companies
Medical Marijuana Sciences, Inc. (MMS)
Silver Spring, Maryland
Medical Marijuana Sciences, Inc. (MMS) is a subsidiary of Nuvilex that was established in early 2013. The initial mission of MMS is to develop treatments, based on constituents of Cannabis, for two of the most serious and deadly forms of cancer – brain and pancreatic cancers.
Nuvilex, Inc.
Silver Spring, Maryland
Nuvilex is a biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology, called Cell-in-a-Box(TM). This unique technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. The Company’s treatment for pancreatic cancer involves the use of the widely used anticancer prodrug, ifosfamide, together with encapsulated live cells that convert ifosfamide into its active or “cancer-killing” form. Nuvilex’s subsidiary, Medical Marijuana Sciences, Inc., is dedicated to the development of cancer treatments based upon …
GW Pharmaceuticals (GWPH)
Porton Down, United Kingdom
GW Pharmaceuticals was founded in 1998 and is listed on both the NASDAQ Global Market (GWPH) and AIM, a market of the London Stock Exchange. GW is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. The Group’s lead programme is the development of a product portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of therapeutic indications, including Sativex® Oromucosal Spray and Epidiolex® for childhood epilepsy.
